Claims for Patent: 9,314,154

Summary for Patent: 9,314,154

Title:	System and method for providing analysis of visual function using a mobile device with display
Abstract:	A visual function evaluation is performed using a sequence of interactions with a mobile device. A patient user may perform a variety of visual tests using the mobile device. The mobile device transmits the test results to a remote server implementing analysis of the visual function results using network service. The network service receives the test results, processes the results, and provides the processed results to a healthcare provider. The processed results may include trends of the user\'s visual function test performance. The healthcare provider, such as a physician, may optimize and administer treatment based on the data. Early detection of changes in visual function can enable the healthcare provider to individualize treatment, helping to prevent vision loss while minimizing visits to the office, discomfort, and expense.
Inventor(s):	Palanker; Daniel (Palo Alto, CA), Blumenkranz; Mark (Los Altos Hills, CA)
Assignee:	The Board of Trustees of the Leland Stanford Junior University (Palo Alto, CA)
Application Number:	14/352,571
Patent Claims:	1. A method for performing a visual function evaluation of a patient with a retinal disease who is under recurrent treatment, the method comprising: executing a patient administered visual function evaluation on a mobile device, wherein the evaluation includes one or more visual function tests pre-selected by a healthcare provider, wherein each test is comprised of a number of steps and the difficulty of a subsequent step is based on a patient's response to a previous step within the test; indicating at least one response to a pre-selected visual function test using a touch screen on the mobile device; transmitting the visual function evaluation results from the mobile device to a remote server; analyzing the results of the visual function evaluation using the remote server to determine trends in the patient's visual function based on the most recent results and previous data; analyzing the trends to determine if a next treatment is to be scheduled; and predicting a time for the next treatment for the patient based on the trends in the patient's visual function. 2. The method of claim 1, wherein the test is pre-selected by the healthcare provider based on the retinal disease. 3. The method of claim 1, wherein the test is pre-selected by the healthcare provider based on the recurrent treatment. 4. The method of claim 3, wherein the recurrent treatment comprises monitoring disease progression or administration of a pharmacological agent. 5. The method of claim 1, wherein the healthcare provider is a doctor, nurse, medical professional, or medical technician. 6. The method of claim 1, wherein the recurrent treatment includes an intraocular injection of a pharmacological agent. 7. The method of claim 6, wherein the pharmacological agent is a VEGF inhibitor. 8. The method of claim 7, wherein the VEGF inhibitor is Lucentis or Avastin. 9. The method of claim 6, wherein the pharmacological agent is Triamcinolone, Ozurdex, VEGF-TRAP, or Visudyne. 10. The method of claim 1, wherein the one or more visual function tests are pre-selected by a healthcare provider based on analysis of the retinal imaging. 11. The method of claim 1, the recurrent treatment further comprising: visiting a physician's office and conducting testing under the guidance of a healthcare provider to determine the need for further treatment. 12. The method of claim 1, wherein the retinal disease is dry macular degeneration disease and the tests are pre-selected to determine progression to wet macular degeneration disease. 13. The method of claim 1, wherein the recurrent treatment is administered by a physician. 14. The method of claim 1, wherein a frequency for performing each of the tests in the visual function evaluation is selected by the healthcare provider. 15. The method of claim 14, wherein the frequency is set by the health care provider based on the patient's responses during a monitoring period or trends in the patient's visual function. 16. The method of claim 1, further comprising indicating at least one response to the pre-selected visual function test with an audible response. 17. The method of claim 1, wherein the analysis of the results of the visual function evaluations includes comparing the results to an expected level of performance for the patient, determined from previous visual function evaluation results. 18. The method of claim 17, further comprising sending an alert to the healthcare provider if the recent results of the visual function evaluation for the patient deviate from the expected level of performance by more than a specified delta level, wherein the delta level is specified by a medical professional. 19. The method of claim 1, wherein the analysis of the trends in the patient's visual function compares the trends in the patient's visual function to trends for other patients or groups of other patients. 20. The method of claim 1, further comprising providing the visual function evaluation results and the results of the analysis to the patient's healthcare provider in order to help determine whether there is a significant deterioration of the visual function that requires a treatment. 21. The method of claim 1, wherein the one or more visual function tests pre-selected by the healthcare provider are based on patient-specific, disease-specific, or treatment-specific criteria. 22. The method of claim 1, wherein the visual function includes one or more functions from the list; visual acuity, contrast sensitivity, low luminance vision, color vision, perimetry, and distortion in the visual field. 23. The method of claim 22, wherein visual acuity is measured by sequentially displaying fonts of various sizes and offering a multiple choice of fonts for a matching selection. 24. The method of claim 22, wherein contrast sensitivity is measured by sequentially displaying fonts of various colors and offering a multiple choice of fonts for a matching selection. 25. The method of claim 22, wherein the contrast sensitivity test begins with a pre-selected background color and a pre-selected font color, wherein the background color or font color changes to decrease a contrast between the background color and font color. 26. The method of claim 1, wherein a level of difficulty for the subsequent step is higher than a level of difficulty for the previous step when the patient enters a correct response in the previous step, wherein the level of difficulty for the subsequent step is lower than the level of difficulty in the previous step when the patient enters an incorrect response in the previous step. 27. The method of claim 26, wherein the visual function test result is determined as the level of difficulty at which two correct responses were obtained, while two incorrect responses have been obtained at a level of difficulty above that. 28. The method of claim 26, wherein the visual function test result is determined as the level of difficulty at which three correct responses were obtained, while three incorrect responses have been obtained at a level of difficulty above that. 29. The method of claim 1, wherein the one or more tests are selected by the healthcare provider using a remote server, and transmitting the selection of the one or more tests to the patient's mobile device. 30. The method of claim 1, further comprising automatically re-testing the patient if the visual function test result is outside of a range of acceptable variation for the patient. 31. The method of claim 1, wherein the retinal diseases include one or more conditions from the list: macular degeneration, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, glaucoma, and chronic retinal detachment.

Details for Patent 9,314,154

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2031-10-17
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2031-10-17
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2031-10-17
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2031-10-17
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2031-10-17